人民卫生出版社系列期刊
ISSN 2096-2738 CN 11-9370/R

中国科技核心期刊(中国科技论文统计源期刊)
中国科学引文数据库(CSCD)来源期刊
《中国学术期刊影响因子年报》统计源期刊
美国化学文摘社(CAS)数据库收录期刊
日本科学技术振兴机构(JST)数据库收录期刊

新发传染病电子杂志 ›› 2025, Vol. 10 ›› Issue (6): 10-15.doi: 10.19871/j.cnki.xfcrbzz.2025.06.002

• WHO结核病报告和指南解读 • 上一篇    下一篇

2014—2024年全球结核病流行趋势与“终止结核病策略”进展:基于WHO全球结核病报告的纵向分析

付亮, 邓国防, 卢水华   

  1. 深圳市第三人民医院/南方科技大学第二附属医院肺病医学部,国家感染性疾病临床医学研究中心(深圳),广东省感染性疾病(结核病)临床研究中心,深圳市结核病临床研究中心,广东 深圳 518112
  • 收稿日期:2025-11-14 出版日期:2025-12-31 发布日期:2026-01-26
  • 通讯作者: 卢水华,Email:lushuihua66@126.com
  • 基金资助:
    1.国家自然科学基金项目(32394014); 2.深圳医学科学院(SMART)医学研究基金项目(C2405002,C2401026)

Global tuberculosis epidemiology and "End TB Strategy" progress, 2014-2024: a longitudinal analysis of WHO global tuberculosis reports

Fu Liang, Deng Guofang, Lu Shuihua   

  1. Department of Pulmonary Medicine, Shenzhen Third People's Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Disease (Shenzhen), Guangdong Provincial Clinical Research Center for Tuberculosis, Shenzhen Clinical Research Center for Tuberculosis, Guangdong Shenzhen 518112, China
  • Received:2025-11-14 Online:2025-12-31 Published:2026-01-26

摘要: 本研究基于WHO 2015—2025年全球结核病报告系列年度数据,分析2014—2024年全球及中国结核病(tuberculosis,TB)相关核心流行病学指标的变化趋势。研究按预设数据框架,从WHO全球结核病报告中提取TB发病数、发病率、死亡数及耐多药/利福平耐药结核病(multidrug/rifampicin-resistant TB,MDR/RR-TB)疾病负担相关年度数据,对全球及中国的上述核心指标进行纵向比较分析。结果显示,2014—2024,全球TB估算发病数维持在千万例量级,由约960万例变动至约1070万例;发病率由约133/10万降至131/10万;TB死亡数由约150万例降至约123万例;MDR/RR-TB估算发病数由约48万例降至39万例。同期,中国TB估算发病数由88.9万例降至69.6万例;发病率由约65/10万降至约49/10万,占全球发病数比例由8.6%降至6.5%;中国MDR/RR-TB估算发病数亦呈下降趋势(由2019的约6.5万例降至2024年的约2.8万例),2024年约占全球总量的7.1%。综上,自2014年以来,全球及中国的TB发病率与死亡数总体呈下降态势,但与“终止结核病策略”设定的2025年TB发病率和死亡率减幅目标相比仍存在一定差距。与此同时,中国TB疾病负担虽持续减轻,但在全球范围内仍面临较重的TB和MDR/RR-TB防控压力。

关键词: 结核病, 流行病学, 全球结核病报告, 终止结核病策略, 纵向分析

Abstract: Based on the series of annual data from the global tuberculosis reports released by the WHO between 2015 and 2025. this study analyzed the changing trends of core epidemiological indicators related to tuberculosis (TB) globally and in China from 2014 to 2024. In accordance with the preset data framework, the study extracted annual data on TB incidence count, incidence rate, mortality count, and the disease burden of multidrug/rifampicin-resistant TB (MDR/RR-TB) from the WHO global tuberculosis reports, and conducted a longitudinal comparative analysis of the above-mentioned core indicators at the global level and in China. The results showed that during the period from 2014 to 2024, the estimated global TB incidence count remained at the scale of 10 million cases, changing from approximately 9.6 million cases to around 10.7 million cases. the incidence rate decreased from about 133 per 100 000 population to 131 per 100 000 population; the number of TB-related deaths dropped from roughly 1.5 million cases to 1.23 million cases; and the estimated incidence count of MDR/RR-TB declined from about 480 000 cases to 390 000 cases. During the same period, in China, the estimated TB incidence count decreased from 889 000 cases to 696 000 cases; the incidence rate fell from around 65 per 100 000 population to about 49 per 100 000 population, with its proportion of the global incidence count dropping from 8.6% to 6.5%. The estimated incidence count of MDR/RR-TB in China also showed a downward trend (decreasing from approximately 65 000 cases in 2019 to about 28 000 cases in 2024), accounting for roughly 7.1% of the global total in 2024. In conclusion, since 2014, the overall TB incidence rate and mortality count have shown a decreasing trend both globally and in China. However, there remains a certain gap compared with the 2025 reduction targets for TB incidence and mortality set by the "End TB Strategy". Meanwhile, although the burden of TB in China has continued to ease, the country still faces considerable pressure in the prevention and control of TB and MDR/RR-TB on a global scale.

Key words: Tuberculosis, Epidemiology, Global tuberculosis report, End Tuberculosis Strategy, Longitudinal analysis

中图分类号: